DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21977 / S-024 / S-025 / S-026

SUPPLEMENT APPROVAL

Shire
Attention: Brian D. Schlag, MA, MS
Director, Global Regulatory Affairs
725 Chesterbrook Blvd.
Wayne PA 19087-5637

Dear Mr. Schlag:

Please refer to your Supplemental New Drug Applications (sNDA) dated March 21, 2012 (S-024), April 24, 2012 (S-025), and June 22, 2012 (S-026), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Vyvanse (lisdexamfetamine mesylate) 20mg, 30mg, 40mg, 50mg, 60mg, 70mg Capsules.

We acknowledge receipt of your amendments dated July 16, 2012 and July 31, 2012.

These "Prior Approval" supplemental new drug applications provide for:

- S-024 – additional instructions for use in the DOSAGE AND ADMINISTRATION section of the Full Prescribing Information (FPI) and the corresponding section of the Medication Guide (FPI) to address the issue of compacted powder when capsules are opened to be added to water.
- S-025 – update the CLINICAL PHARMACOLOGY Drug Interactions and Special Populations subsections of the FPI to include new information from a venlafaxine drug interaction study and geriatric pharmacokinetic study, respectively.
- S-026 – update Section 7 (Drug Interactions) of the Vyvanse FPI to be consistent with the current FDA Guidance, "*Drug Interactions Studies – Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations*".

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content

of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, email Juliette Touré, PharmD, Senior Regulatory Project Manager, at Juliette.Toure@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Thomas Laughren, MD
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:

Content of Labeling – Full Prescribing Information and Medication Guide

---

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JULIETTE T TOURE
11/16/2012

THOMAS P LAUGHREN
11/19/2012